In this ongoing proof-of-concept study, we observed trends toward improvement in depression, fatigue, and pain during 8 weeks of C1-INH therapy in patients with SARS-CoV-2 post-viral fatigue syndrome. This evidence concerns the gene SERPING1 and major depressive disorder.